Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: A systematic review and meta-analysis

International Journal of Clinical Practice

Volumn 68, Issue 2, 2014, Pages 255-261

  Ehret, M ^a   Sobieraj, D M ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; CHEMICALLY INDUCED; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C, CHRONIC; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84893673343     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12268     Document Type: Article

References (34)

1. Wasley A, Alter MJ,. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
2. Schiff ER,. Diagnosing and treating hepatitis C virus infection. Am J Manag Care 2011; 17: S108-15.
3. Seeff LB, Hoofnagle JH,. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003; 7: 261-87.
4. Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708-14.
5. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alpha, and depression. Hepatology 2000; 31: 1207-11.
6. Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34-8.
7. Malaguarnera M, Laurina A, Di Fazio I, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 273-8.
8. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538-44.
9. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491-8.
10. Ademmer K, Beutel M, Bretzel R, et al. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics 2001; 42: 365-7.
11. Martin-Santos R, Diez-Quevedo C, Castellvi P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008; 27: 257-65.
12. Bronowicki JP, Canva V, Tran A, et al. Assessment of paroxetine in the prevention of depression in patients with chronic hepatitis C treated by PEG-interferon alpha plus ribavirin: a multicentric, double-blinded, randomized study. Gastroenterology 2011; 140: S790.
13. de Knegt RJ, Bezemer G, Van Gool AR, et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alpha-2a and ribavirin for hepatitis C. Aliment Pharmacol Ther 2011; 34: 1306-17.
14. Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferonalfa-2a induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 522-8.
15. Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind placebo-controlled trial. Psychosomatics 2010; 51: 401-8.
16. Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103: 83-90.
17. Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease. Ann Intern Med 2012; 157: 94-103.
18. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-74.
19. Higgins JPT, Green S,. (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org
20. Follman D, Elliot P, Suh I, et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-73.
21. Hafizi S, Favaron E,. Interferon-induced depression: mechanisms and management. Br J Hosp Med 2007; 68: 307-10.
22. Turner EH, Blackwell AD,. 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses 2005; 65: 138-44.
23. Baraldi S, Hepgul N, Mondelli V, et al. Symptomatic treatment of interferon-alpha induced depression in hepatitis C: a systematic review. J Clin Psychopharmcol 2012; 32: 531-43.
24. Loftis JM, Hauser P,. Safety of the treatment of interferon-alpha-induced depression. Psychosomatics 2003; 44: 524-6.
25. Beckwith AR,. The precipitation of mania by citalopram in a patient with interferon-induced depression. Psychosomatics 2008; 49: 362-3.
26. Wu PL, Liao KF, Peng CY, et al. Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection. Gen Hosp Psychiatry 2007; 29: 374-6.
27. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105-23.
28. Montgomery SA, Asberg M,. A new depressive scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
29. Capuron L, Miller AH,. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004; 56: 819-24.
30. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
31. Victrelis (boceprevir) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme, 2011.
32. Incivek (telaprevir) [package insert]. Cambridge, MA: Vertex Pharmaceuticals Incorporated, 2012.
33. Quelhas R, Lopes A,. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psychiatr Pract 2009; 15: 262-81.
34. Martin KA, Krahn LE, Balan V, et al. Selective serotonin reuptake inhibitors in the context of hepatitis C infection: reexamining the risks of bleeding. J Clin Psychiatry 2007; 68: 1024-6.